Research Infrastructure Development for Interdisciplinary Aging Studies (R61/R33 - Clinical Trial Optional)

Background
This FOA invites applications that propose to develop novel research infrastructure that will advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. The National Institute on Aging (NIA) is the primary participating organization, with additional co-funding opportunities available through the Office of Research on Women's Health (ORWH). The FOA aims to provide resources to interdisciplinary groups collaborating to develop effective research infrastructure on important aging topics.

Grant Details
Applications submitted to this FOA should propose the development of research infrastructure to advance specific topics in aging science that require interdisciplinary partnerships or collaborations. The range of disciplines included in the application should be appropriate to the scientific goals of the proposed collaboration. The FOA supports the establishment of new interdisciplinary collaborations or the development of existing interdisciplinary collaborations in significantly new directions.
Research infrastructure supported through this FOA must endeavor to benefit the larger research community, as opposed to solely supporting the investigators' research interests. The FOA also encourages interactions between academic investigators and the biotechnology sector.

Eligibility Requirements
Eligible applicants include higher education institutions, nonprofits, for-profit organizations, state and local governments, federal agencies, U.S. territories or possessions, and various other entities as detailed in Section III of the document. Foreign institutions are not eligible to apply directly but may participate as foreign components.

Period of Performance
The duration of the entire R61/R33 award may not exceed 5 years, with up to 2 years of support for initial developmental activities (R61 phase) and up to 3 years of support for expanded activities (R33 phase). All applications are due by 5:00 PM local time of applicant organization.

Grant Value
Annual direct costs must remain under $500,000 in both R61 and R33 phases. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.